State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOSDefense World · 4 days ago
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?Zacks Investment Research · Oct 14, 2026
Glaukos: The Second J-Code Rewrites The Risk MathSeeking Alpha · Oct 9, 2026
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealZacks Investment Research · Oct 9, 2026
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye TherapyBenzinga · Oct 9, 2026
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract SurgeryBusiness Wire · Oct 9, 2026Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.21 | -$0.14 | Beat |
| Apr 29, 2026 | -$0.30 | -$0.18 | Beat |
| Feb 17, 2026 | -$0.22 | -$0.28 | Miss |
| Oct 29, 2025 | -$0.27 | -$0.16 | Beat |
| Jul 30, 2025 | -$0.26 | -$0.24 | Beat |
| Apr 30, 2025 | -$0.33 | -$0.22 | Beat |